blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP0935468

EP0935468 - USE OF CYTOKINES AND CYTOTOXIC SUBSTANCES IN A NEW METHOD TO TREAT TUMORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.05.2003
Database last updated on 14.11.2024
Most recent event   Tooltip09.05.2003No opposition filed within time limitpublished on 25.06.2003  [2003/26]
Applicant(s)For all designated states
MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN
Robert-Rössle-Strasse 10
13125 Berlin / DE
[2002/27]
Former [1999/33]For all designated states
MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN
Robert-Rössle-Strasse 10
D-13125 Berlin / DE
Inventor(s)01 / STEIN, Ulrike
Theodor-Brugsch-Strasse 36
D-13125 Berlin / DE
02 / WALTHER, Wolfgang
Theodor-Brugsch-Strasse 36
D-13125 Berlin / DE
03 / SCHLAG, Peter
Frohnauer Strasse 17a
D-13467 Berlin / DE
[1999/33]
Representative(s)Baumbach, Friedrich
Patentanwalt
Robert-Rössle-Strasse 10
13125 Berlin / DE
[N/P]
Former [1999/33]Baumbach, Friedrich, Dr.
Biotez Berlin/Buch Robert-Rössle-Strasse 10
13125 Berlin / DE
Application number, filing date97942950.319.09.1997
[1999/33]
WO1997EP05133
Priority number, dateEP1996025020620.09.1996         Original published format: EP 96250206
[1999/47]
Former [1999/33]DE196295020620.09.1996
Filing languageDE
Procedural languageDE
PublicationType: A1 Application with search report
No.:WO9811911
Date:26.03.1998
Language:DE
[1998/12]
Type: A1 Application with search report 
No.:EP0935468
Date:18.08.1999
Language:DE
The application published by WIPO in one of the EPO official languages on 26.03.1998 takes the place of the publication of the European patent application.
[1999/33]
Type: B1 Patent specification 
No.:EP0935468
Date:03.07.2002
Language:DE
[2002/27]
Search report(s)International search report - published on:EP26.03.1998
ClassificationIPC:A61K38/20, A61K38/19, // A61K31/00, A61P35/00
[2001/36]
CPC:
A61K38/191 (EP,US); A61K38/2013 (EP,US); A61P35/00 (EP)
Former IPC [1999/33]A61K38/20, A61K38/19, // A61K31/00
Designated contracting statesAT,   BE,   CH,   DE,   FR,   GB,   IT,   LI,   NL,   SE [1999/33]
TitleGerman:VERWENDUNG VON CYTOKINEN UND CYTOTOXISCHEN SUBSTANZEN IN EINEM NEUEN VERFAHREN ZUR TUMORBEHANDLUNG[1999/33]
English:USE OF CYTOKINES AND CYTOTOXIC SUBSTANCES IN A NEW METHOD TO TREAT TUMORS[1999/33]
French:UTILISATION DE CYTOKINES ET DE SUBSTANCES CYTOTOXIQUES DANS UNE NOUVELLE METHODE DE TRAITEMENT DE TUMEURS[1999/33]
Entry into regional phase07.04.1999National basic fee paid 
07.04.1999Designation fee(s) paid 
07.04.1999Examination fee paid 
Examination procedure04.04.1998Request for preliminary examination filed
International Preliminary Examining Authority: EP
07.04.1999Examination requested  [1999/33]
31.07.2000Despatch of a communication from the examining division (Time limit: M04)
20.11.2000Reply to a communication from the examining division
15.10.2001Despatch of communication of intention to grant (Approval: Yes)
07.01.2002Communication of intention to grant the patent
15.02.2002Fee for grant paid
15.02.2002Fee for publishing/printing paid
Opposition(s)04.04.2003No opposition filed within time limit [2003/26]
Fees paidRenewal fee
13.09.1999Renewal fee patent year 03
13.09.2000Renewal fee patent year 04
22.11.2001Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
30.09.200105   M06   Fee paid on   22.11.2001
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO9601121  (GENENTECH INC [US]) [X] 1-10 * the whole document *;
 [X]  - HO R. ET AL., "Development of Safe and Effective Adriamycin Plus Inteleukin 2 Therapy Against Both Adriamycin-Sensitive and -Resistant Lymphomas", ONCOLOGY RESEARCH, (1993), vol. 5, no. 9, pages 373 - 381, XP000645160 [X] 1-10 * the whole document *
 [X]  - NABIOULLIN R ET AL, "Influence of systemic chemotherapy on anti-P-glycoprotein antibody-dependent cell-mediated cytotoxicity in patients with small cell lung cancer.", JAPANESE JOURNAL OF CLINICAL ONCOLOGY 25 (4). 1995. 124-130, XP000645157 [X] 1-10 * the whole document *
 [X]  - REGENASS U. ET AL., "TNF in combination with cytostatic agents", EXPERIENTIA, (1986), vol. 42, no. 6, page 701, XP002026299 [X] 1-10 * the whole document *
 [DX]  - WALTHER W ET AL, "Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: Increased cytotoxicity of MDR relevant drugs.", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 120 (8). 1994. 471-478, XP000645076 [DX] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1007/BF01191800
 [DX]  - WALTHER W ET AL, "Gene transfer of human TNF-alpha into glioblastoma cells permits modulation of mdr1 expression and potentiation of chemosensitivity.", INTERNATIONAL JOURNAL OF CANCER 61 (6). 1995. 832-839, XP000645062 [DX] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1002/ijc.2910610615
 [PX]  - WALTHER W ET AL, "Employment of the mdr1 promoter for the chemotherapy-inducible expression of therapeutic genes in cancer gene therapy.", GENE THERAPY 4 (6). 1997. 544-552, XP002052739 [PX] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1038/sj.gt.3300451
 [PX]  - STEIN U ET AL, "Modulation of mdr1 expression by cytokines in human colon carcinoma cells: An approach for reversal of multidrug resistance.", BRITISH JOURNAL OF CANCER 74 (9). 1996. 1384-1391, XP002052740 [PX] 1-10 * the whole document *
 [PX]  - STEIN U ET AL, "Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.", JOURNAL OF THE NATIONAL CANCER INSTITUTE (BETHESDA) 88 (19). 1996. 1383-1392, XP002052741 [PX] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1093/jnci/88.19.1383
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.